We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through lice... Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals. Show more
DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of...
DURHAM, N.C., April 16, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that on April 10, 2024, the Compensation Committee of Chimerix’s Board of Directors granted inducement...
DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of...
– ONC201 ACTION Study Progressing; Reiterate Interim OS Data Expected in 2025, Final OS Data Expected in 2026 – – Phase 2 ONC201 Data Published in Peer-Reviewed Journal of Clinical Oncology – –...
DURHAM, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0269 | 3.03611738149 | 0.886 | 0.94 | 0.88 | 194701 | 0.90632496 | CS |
4 | -0.1371 | -13.0571428571 | 1.05 | 1.07 | 0.88 | 287892 | 0.95877614 | CS |
12 | -0.0171 | -1.83870967742 | 0.93 | 1.3 | 0.88 | 445190 | 1.05696103 | CS |
26 | -0.0771 | -7.78787878788 | 0.99 | 1.3 | 0.88 | 398241 | 1.0112102 | CS |
52 | -0.2571 | -21.9743589744 | 1.17 | 1.57 | 0.88 | 646218 | 1.13736937 | CS |
156 | -8.3771 | -90.1733046286 | 9.29 | 9.29 | 0.88 | 1350618 | 2.87274278 | CS |
260 | -1.6771 | -64.7528957529 | 2.59 | 11.5696 | 0.88 | 1069857 | 3.21720531 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions